Asset
Vepdegestrant
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04072952 | phase1_2 | completed | 2019-08-05 | 2024-09-13 | Arvinas Estrogen Receptor, Inc. | A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer |
| NCT05549505 | phase2 | completed | 2023-02-15 | 2024-07-13 | Arvinas Inc. | A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery |
FDA applications (0)
This company has no applications containing this asset.